RecruitingNot Applicable

Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy

Egypt100 participantsStarted 2023-06-01

Plain-language summary

The study aims to Compare the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) (using MNS questionnaire, ,Inspection, vibratory sensation, Ankle reflexes Exam, 10 g monofilament needle examination), routine NCS, and the U/S of the median, posterior tibial, and sural nerves in identifying diabetic peripheral neuropathy in patients recently diagnosed with type 2 diabetes.

Who can participate

Age range33 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ü Age: 30-55 y ü Type of diabetes: Type 2 ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria Exclusion Criteria: * Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

What they're measuring

Early detection of Diabetic Neuropathy

Timeframe: Searching in patients diagnosed within 1 year or less

Trial details

NCT IDNCT06514846

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-01

Contact for this trial

Reda Khalaf Allah Khalil, Resident

0102 006 5913 redakhalaf@med.sohag.edu.eg

View on ClinicalTrials.gov More Diabetic Polyneuropathy trials